Compare NTNX & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | HOLX |
|---|---|---|
| Founded | 2009 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Electronics |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 16.6B |
| IPO Year | 2016 | 1990 |
| Metric | NTNX | HOLX |
|---|---|---|
| Price | $53.68 | $74.85 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 13 |
| Target Price | $74.20 | ★ $79.10 |
| AVG Volume (30 Days) | ★ 4.3M | 2.9M |
| Earning Date | 02-25-2026 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.76 | ★ 2.49 |
| Revenue | $2,617,547,000.00 | ★ $4,100,500,000.00 |
| Revenue This Year | $14.23 | $6.72 |
| Revenue Next Year | $14.00 | $5.48 |
| P/E Ratio | $70.02 | ★ $30.07 |
| Revenue Growth | ★ 17.45 | 1.74 |
| 52 Week Low | $46.12 | $51.90 |
| 52 Week High | $83.36 | $75.34 |
| Indicator | NTNX | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 55.15 | 57.54 |
| Support Level | $50.27 | $74.72 |
| Resistance Level | $54.11 | $75.05 |
| Average True Range (ATR) | 1.34 | 0.20 |
| MACD | 0.74 | -0.04 |
| Stochastic Oscillator | 93.40 | 72.22 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.